Other substances

Topotecan

A topoisomerase I inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
1
 Clinical trials

General information

Topotecan is an FDA-approved TOP1 topoisomerase inhibitor. The siRNA knockdown of TOP1 has been shown to suppress the upregulation of several genes associated with SARS-CoV-2 infection progression, several of which are involved in inflammatory responses. Similarly, topotecan treatment experimentally dampened expression of several pro-inflammatory genes in vitro and in lungs of a hamster model after a viral challenge. The drug also reduced lung pathology. In a mouse model, early and intermediate treatment did not reduce mortality due to the drug’s mechanism of action. On the other hand, late treatment significantly increased survival of the infected mice compared to control (Ho et al., 2021).

Topotecan on DrugBank
Topotecan on PubChem
Topotecan on Wikipedia


Marketed as

HYCAMTIN; POTACTASOL; TOPOTECAN

 

Structure image - Topotecan

CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O


 

Supporting references

Link Tested on Impact factor Notes Publication date
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation
Small molecule Animal model In vitro Mechanism 		A549-ACE2 cells; Vero E6 cells; B6.Cg-Tg(K18-866 ACE2)2Prlmn/J mice; golden Syrian hamsters; SARS-CoV-2 isolates USA-WA1/2020 and HKG/13_P2/2020 38.64

Topotecan treatment dampened expression of several pro-inflammatory genes in vitro and in lungs of a hamster model after a viral challenge. The drug also reduced lung pathology. In a mouse model, early and intermediate treatment did not reduce mortality due to the drug’s mechanism of action. On the other hand, late treatment significantly increased survival of the infected mice compared to control.

 Mar/30/2021

AI-suggested references

Link Publication date
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach
Feb/04/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05083000 Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care Recruiting Phase 1 Aug/16/2021 Mar/31/2022
  • Alternative id - TOTORO1
  • Interventions - Drug: Topotecan
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Christian Medical College, Vellore, Tamil Nadu, India
  • Study designs - Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 24
  • Age - 21 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Maximal tolerable dose of Topotecan|Rate of reduction in the duration of supplemental oxygen requirement in participants|Rate of treatment related CTCAE grade 3/4 haematological toxicity|Number of participant with Serious Adverse Events|Proportion of patients requiring ICU care|Proportion of patients requiring mechanical ventilation|Time to discharge|Proportion of patients with secondary infections|Proportion of patients who died after enrolment into trial
Export (.csv)